CLLS
Cellectis S.A.
$2.81
-0.07 (-2.26%)
At close · Jul 15
Market Cap
$268.86M
Shares
100,698,158
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.81
Open$2.87
Day$2.79–2.87
52W$1.77–5.48
Avg vol 30d38K
Short int322K · 0.3% float · 8.9d
Short vol45%
Last earningsJun 30, 2025
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−15%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
28%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−32%
trailing
YTD return
−42%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
1 of 32 funds reported for Jun 30 · net -271 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.32% of float · ▼ -13.3% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — mid 3-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
28%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
1 of 32 funds reported for Jun 30 · net -271 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.32% of float · ▼ -13.3% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $3 · 28%
52-wk high $5
vs 200-day avg -26%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLLS
this stock
Cellectis S.A.
|
$268.86M | -41.9% | — | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +2.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLLS | -9.1% | -9.7% | -31.6% | -6.3% | -41.9% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -10.3% | -9.5% | -41.8% | -7.4% | -52.6% |